Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.

Abstract	A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.
Authors	Shuchun Chen, Seong-Jin Yu, Yazhou Li, Daniela Lecca, Elliot Glotfelty, Hee Kyung Kim, Ho-Il Choi, Barry J Hoffer, Nigel H Greig, Dong Seok Kim, Yun Wang
Journal	Scientific reports (Sci Rep) Vol. 8 Issue 1 Pg. 13953 (Sep 12 2018) ISSN: 2045-2322 [Electronic] England
PMID	30209317 (Publication Type: Published Erratum)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!